Galliprant

RSS

grapiprant

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Galliprant. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Galliprant.

For practical information about using Galliprant, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 30/05/2018

Authorisation details

Product details
Name
Galliprant
Agency product number
EMEA/V/C/004222
Active substance
grapiprant
International non-proprietary name (INN) or common name
grapiprant
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QM01AX92
Publication details
Marketing-authorisation holder
Elanco GmbH
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
09/01/2018
Contact address
Heinz-Lohmann-Str 4
27472 Cuxhaven
Germany

Product information

25/05/2018 Galliprant - EMEA/V/C/004222 - T/0002

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Other anti inflammatory and antirheumatic agents
  • non steroids

Therapeutic indication

For the treatment of pain associated with mild to moderate osteoarthritis in dogs.

Assessment history

How useful was this page?

Add your rating